Parkinson’s disease

Pelvic Organ Dysfunction in Neurological Disease: Clinical Management and Rehabilitation

Volumn , Issue , 2010, Pages 187-205

  Ryuji, Sakakibara ^a   Fowler, Clare J ^b,c   Takamichi, Hattori ^d  

^a TOHO UNIVERSITY   (Japan)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84927038043     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511762611.014     Document Type: Chapter

References (129)

1. Lang AE, Obeso JA. Challenges in Parkinson’s disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004;3:309-16.
2. Sakakibara R, Shinotoh H, Uchiyama T, et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson’s disease. Auton Neurosci2001;92:76-85.
3. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 2001;57:456-62.
4. Ueki A, Otsuka M. Life style risks of Parkinson’s disease: Association between decreased water intake and constipation. J Neurol 2004;251 (Suppl 7):18-23.
5. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res2004;318:121-34.
6. Braak H, Rub U, Gai WP, Del Tredici K. Idiopathic Parkinson’s disease: Possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 2003;110:517-36.
7. Hawkes CH, Del Tredici K, Braak H. Parkinson’s disease: A dual-hit hypothesis. Neuropathol Appl Neurobiol 2007;33:599-614.
8. Hansen MB. Neurohumoral control of gastrointestinal motility. Physiol Res 2003;52:1-30.
9. Liu MT, Rayport S, Jiang Y, Murphy DL, Gershon MD. Expression and function of 5-HT3 receptors in the enteric neurons of mice lacking the serotonin transporter. Am J Physiol Gastrointest Liver Physiol 2002;283:1398-411.
10. Tonini M. 5-Hydroxytryptamine effects in the gut: the 3, 4, and 7 receptors. Neurogastroenterol Motil 2005;17:637-42.
11. Walker JK, Gainetdinov RR, Mangel AW, Caron MG, Shetzline MA. Mice lacking the dopamine transporter display altered regulation of distal colonic motility. Am J Physiol Gastrointest Liver Physiol 2000; 279:311-8.
12. Anlauf M, Schafer MK, Eiden L, Weihe E. Chemical coding of the human gastrointestinal nervous system: Cholinergic, VIPergic, and catecholaminergic phenotypes. J Comp Neurol 2003;459:90-111.
13. Vaughan CJ, Aherne AM, Lane E, et al. Identification and regional distribution of the dopamine D(1A) receptor in the gastrointestinal tract. Am J Physiol Regul Integr Comp Physiol 2000;279:599-609.
14. Haskel Y, Hanani M. Inhibition of gastrointestinal motility by MPTP via adrenergic and dopaminergic mechanisms. Dig Dis Sci 1994;39:2364-7.
15. Banach T, Zurowski D, Gil K, et al. Peripheral mechanisms of intestinal dysmotility in rats with salsolinol induced experimental Parkinson’s disease. J Physiol Pharmacol 2006;57:291-300.
16. Miyamoto-Kikuta S, Ezaki T, Komuro T. Distribution and morphological characteristics of the interstitial cells of Cajal in the ileocaecal junction of the guinea-pig. Cell Tissue Res 2009;338:29-35.
17. Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci Lett 2006;396:67-72.
18. Qualman SJ, Haupt HM, Yang P, Hamilton SR. Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson’s disease. Gastroenterology 1984;87:848-56.
19. Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson’s disease. Eur Neurol 1997;38(Suppl 2):2-7.
20. Wang SJ, Fuh JL, Shan DE, et al. Sympathetic skin response and R-R interval variation in Parkinson’s disease. Mov Disord 1993;8:151-7.
21. Gai WP, Blessing WW, Blumbergs PC. Ubiquitin-positive degenerating neurites in the brainstem in Parkinson’s disease. Brain 1995;118(Pt 6):1447-59.
22. Gravante G, Sabatino M, Sorbera F, Ferraro G, La Grutta V. Effects of substantia nigra stimulation on electrical and mechanical activities of the duodenojejunal loop, in the cat. Arch Int Physiol Biochim1985;93:93-100.
23. Jing H, Lin KW, Mei MH. Participation of dopamine on the muscarinergic inhibitory effect of substance P on gastric myoelectric activity and motility. Sheng Li Xue Bao 1995;47:245-52.
24. Bueno L, Gue M, Fabre C, Junien JL. Involvement of central dopamine and D1 receptors in stress-induced colonic motor alterations in rats. Brain Res Bull1992;29:135-40.
25. Edwards LL, Pfeiffer RF, Quigley EM, Hofman R, Balluff M. Gastrointestinal symptoms in Parkinson’s disease. Mov Disord 1991;6:151-6.
26. Singer C, Weiner W, Sanchez-Ramos JR. Autonomic dysfunction in men with Parkinson’s disease. European Neurology 1992;32:134-40.
27. Siddiqui MF, Rast S, Lynn MJ, Auchus AP, Pfeiffer RF. Autonomic dysfunction in Parkinson’s disease: A comprehensive symptom survey. Parkinsonism Relat Disord 2002;8:277-84.
28. Robson KM, Kiely DK, Lembo T. Development of constipation in nursing home residents. Dis Colon Rectum 2000;43:940-3.
29. Jost WH. Gastrointestinal motility problems in patients with Parkinson’s disease. Effects of antiparkinsonian treatment and guidelines for management. Drugs Aging 1997;10:249-58.
30. Shimada J, Sakakibara R, Uchiyama T, et al. Intestinal pseudo-obstruction and neuroleptic malignant syndrome in a chronically constipated parkinsonian patient. Eur J Neurol 2006;13:306-7.
31. Yokoyama T, Hasegawa I. Ileus in Parkinson’s disease. Neurological Medicine 2007;66:6-11.
32. Rosenthal MJ, Marshall CE. Sigmoid volvulus in association with parkinsonism. Report of four cases. J Am Geriatr Soc 1987;35:683-4.
33. Jost WH, Schrank B. Defecatory disorders in de novo Parkinsonians - colonic transit and electromyogram of the external anal sphincter. Wien Klin Wochenschr1998;110:535-7.
34. Sakakibara R, Odaka T, Uchiyama T, et al. Colonic transit time and rectoanal videomanometry in Parkinson’s disease. J Neurol Neurosurg Psychiatry2003;74:268-72.
35. Ashraf W, Pfeiffer RF, Park F, Lof J, Quigley EM. Constipation in Parkinson’s disease: objective assessment and response to psyllium. Mov Disord1997;12:946-51.
36. Libelius R, Johanson JF. Quantitative electromyography of the external anal sphincter in Parkinson’s disease and multiple system atrophy. Muscle & Nerve 2000;23:1250-6.
37. Stocchi F, Badiali D, Vacca L, et al. Anorectal function in multiple system atrophy and Parkinson’s disease. Mov Disord 2000;15:71-6.
38. Ito T, Sakakibara R, Uchiyama T, et al. Videomanometry of the pelvic organs: A comparison of the normal lower urinary and gastrointestinal tracts. Int J Urol 2006;13:29-35.
39. Araki I, Kitahara M, Oida T, Kuno S. Voiding dysfunction and Parkinson’s disease: urodynamic abnormalities and urinary symptoms. J Urol2000;164:1640-3.
40. Iscoe S. Control of abdominal muscles. Prog Neurobiol 1998;56:433-506.
41. Fontana GA, Pantaleo T, Lavorini F, Benvenuti F, Gangemi S. Defective motor control of coughing in Parkinson’s disease. Am J Respir Crit Care Med1998;158:458-64.
42. Mathers SE, Kempster PA, Law PJ, et al. Anal sphincter dysfunction in Parkinson’s disease. Arch Neurol1989;46:1061-4.
43. Edwards LL, Quigley EM, Harned RK, Hofman R, Pfeiffer RF. Defecatory function in Parkinson’s disease: response to apomorphine. Ann Neurol1993;33:490-3.
44. Astarloa R, Mena MA, Sanchez V, de la Vega L, de Yebenes JG. Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease. Clin Neuropharmacol 1992;15:375-80.
45. Ashraf W, Wszolek ZK, Pfeiffer RF, et al. Anorectal function in fluctuating (on-off) Parkinson’s disease: Evaluation by combined anorectal manometry and electromyography. Mov Disord 1995;10:650-7.
46. Eichhorn TE, Oertel WH. Macrogol 3350/electrolyte improves constipation in Parkinson’s disease and multiple system atrophy. Mov Disord 2001;16:1176-7.
47. Sakakibara R, Yamaguchi T, Uchiyama T, et al. Calcium polycarbophil improves constipation in primary autonomic failure and multiple system atrophy subjects. Mov Disord 2007;22:1672-3.
48. Soykan I, Sarosiek I, Shifflett J, Wooten GF, McCallum RW. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson’s disease. 1997;12:952-7.
49. Shindler JS, Finnerty GT, Towlson K, et al. Domperidone and levodopa in Parkinson’s disease. Br J Clin Pharmacol 1984;18:959-62.
50. Djaldetti R, Koren M, Ziv I, Achiron A, Melamed E. Effect of cisapride on response fluctuations in Parkinson’s disease. Mov Disord 1995;10:81-4.
51. Liu Z, Sakakibara R, Odaka T, et al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord 2005;20:680-6.
52. Sullivan KL, Staffetti JF, Hauser RA, Dunne PB, Zesiewicz TA. Tegaserod (Zelnorm) for the treatment of constipation in Parkinson’s disease. Mov Disord2006;21:115-6.
53. Cadeddu F, Bentivoglio AR, Brandara F, et al. Outlet type constipation in Parkinson’s disease: results of botulinum toxin treatment. Aliment Pharmacol Ther2005;22:997-1003.
54. Chiarioni G, Heymen S, Whitehead WE. Biofeedback therapy for dyssynergic defecation. World J Gastroenterol 2006;12:7069-74.
55. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
56. Staskin DS, Vardi Y, Siroky MA. Post-prostatectomy incontinence in the parkinsonian patient: the significance of poor voluntary sphincter control. J Urol1988;140:117-8.
57. Routh JC, Crimmins CR, Leibovich BC, Elliott DS. Impact of Parkinson’s disease on continence after radical prostatectomy. Urology 2006;68:575-7.
58. Roth B, Studer UE, Fowler CJ, Kessler TM. Benign prostatic obstruction and parkinson’s disease - should transurethral resection of the prostate be avoided? J Urol 2009;181:2209-13.
59. Andersen JT, Bradley WE. Cystometric, sphincter and electromyelographic abnormalities in Parkinson’s disease. J Urol 1976;116:75-8.
60. Berger Y, Blaivas JG, DeLaRocha ER, Salinas JM. Urodynamic findings in Parkinson’s disease. J Urol1987;138:836-8.
61. Pavlakis AJ, Siroky MB, Goldstein I, Krane RJ. Neurourologic findings in Parkinson’s disease. J Urol1983;129:80-3.
62. Araki I, Kuno S. Assessment of voiding dysfunction in Parkinson’s disease by the international prostate symptom score. J Neurol Neurosurg Psychiatry2000;68:429-33.
63. Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord 2006;21:916-23.
64. Martinez-Martin P, Schapira AH, Stocchi F, et al. Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 2007;22:1623-9.
65. Sakakibara R, Shinotoh H, Uchiyama T, et al. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson’s disease with urinary dysfunction. J Neurol Sci 2001;187:55-9.
66. Winge K, Friberg L, Werdelin L, Nielsen KK, Stimpel H. Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson’s disease. Eur J Neurol 2005;12:842-50.
67. Yoshimura N, Sasa M, Yoshida O, Takaori S. Mediation of micturition reflex by central norepinephrine from the locus coeruleus in the cat. J Urol 1990;143:840-3.
68. Seki S, Igawa Y, Kaidoh K, et al. Role of dopamine D1 and D1 receptors in the micturition reflex in conscious rats. Neurourol Urodyn 2001;20:105-13.
69. Yamamoto T, Sakakibara R, Nakazawa K, et al. Effects of electrical stimulation of the striatum on bladder activity in cats. Neurourol Urodyn 2009;28:549-54.
70. Winge K, Fowler CJ. Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord 2006;21:737-45.
71. Finazzi-Agro E, Peppe A, D’Amico A, et al. Effects of subthalamic nucleus stimulation on urodynamic findings in patients with Parkinson’s disease. J Urol2003;169:1388-91.
72. Sakakibara R, Nakazawa K, Uchiyama T, et al. Effects of subthalamic nucleus stimulation on the micturation reflex in cats. Neuroscience 2003;120:871-5.
73. Seif C, Herzog J, van der Horst C, et al. Effect of subthalamic deep brain stimulation on the function of the urinary bladder. Ann Neurol 2004;55:118-20.
74. Herzog J, Weiss PH, Assmus A, et al. Subthalamic stimulation modulates cortical control of urinary bladder in Parkinson’s disease. Brain 2006; 129:3366-75.
75. Gerschlager W, Alesch F, Cunnington R, et al. Bilateral subthalamic nucleus stimulation improves frontal cortex function in Parkinson’s disease. An electrophysiological study of the contingent negative variation. Brain 1999;122(Pt 12):2365-73.
76. Winge K, Werdelin LM, Nielsen KK, Stimpel H. Effects of dopaminergic treatment on bladder function in Parkinson’s disease. Neurourol Urodyn 2004; 23:689-96.
77. Uchiyama T, Sakakibara R, Hattori T, Yamanishi T. Short-term effect of a single levodopa dose on micturition disturbance in Parkinson’s disease patients with the wearing-off phenomenon. Mov Disord2003;18:573-8.
78. Christmas T, Kempster P, Chapple C, et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 1988;2:1451-3.
79. Fitzmaurice H, Fowler CJ, Rickards D, et al. Micturition disturbance in Parkinson’s disease. Br J Urol 1985;57:652-6.
80. Aranda B, Cramer P. Effects of apomorphine and L-dopa on the parkinsonian bladder. Neurourol Urodyn 1993;12:203-9.
81. Brusa L, Petta F, Pisani A, et al. Central acute D2 stimulation worsens bladder function in patients with mild Parkinson’s disease. J Urol 2006; 175:202-6.
82. Yoshimura N, Mizuta E, Yoshida O, Kuno S. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys. J Pharmacol Exp Ther 1998;286:228-33.
83. Kuno S, Mizuta E, Yamasaki S, Araki I. Effects of pergolide on nocturia in Parkinson’s disease: three female cases selected from over 400 patients. Parkinsonism Relat Disord 2004;10:181-7.
84. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology2005;65:1863-72.
85. Sakakibara R, Ito T, Uchiyama T, et al. Lower urinary tract function in dementia of Lewy body type. J Neurol Neurosurg Psychiatry 2005;76:729-32.
86. Kay GG, Abou-Donia MB, Messer WS, et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 2005;53:2195-201.
87. Kay GG, Granville LJ. Antimuscarinic agents: Implications and concerns in the management of overactive bladder in the elderly. Clin Ther2005;27:127-38.
88. Ehrt U, Broich K, Larsen JP, Ballard C, Aarsland D. Use of drugs with anticholinergic effect and impact on cognition in Parkinson’s disease: A cohort study. J Neurol Neurosurg Psychiatry 2010;81:160-5.
89. Halliday GM, Blumbergs PC, Cotton RG, Blessing WW, Geffen LB. Loss of brainstem serotonin- and substance P-containing neurons in Parkinson’s disease. Brain Res1990;510:104-7.
90. Ito T, Sakakibara R, Nakazawa K, et al. Effects of electrical stimulation of the raphe area on the micturition reflex in cats. Neuroscience 2006; 142:1273-80.
91. Andersson KE. Treatment of overactive bladder: other drug mechanisms. Urology 2000;55:51-7.
92. Schurch B, Hauri D, Rodic B, et al. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: A prospective study in 24 spinal cord injury patients. J Urol 1996;155:1023-9.
93. Kalsi V, Gonzales G, Popat R, et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol 2007;62:452-7.
94. Giannantoni A, Rossi A, Mearini E, et al. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson’s disease and multiple system atrophy. J Urol 2009;182:1453-7.
95. Andersson KE. Pharmacology of penile erection. Pharmacol Rev 2001;53:417-50.
96. Montorsi F, Perani D, Anchisi D, et al. Apomorphine-induced brain modulation during sexual stimulation: A new look at central phenomena related to erectile dysfunction. Int J Impot Res 2003; 15:203 - 9.
97. Langston JW, Forno LS. The hypothalamus in Parkinson disease. Ann Neurol 1978;3:129-33.
98. Bellomo G, Santambrogio L, Fiacconi M, Scarponi AM, Ciuffetti G. Plasma profiles of adrenocorticotropic hormone, cortisol, growth hormone and prolactin in patients with untreated Parkinson’s disease. J Neurol 1991; 238:19-22.
99. Ready RE, Friedman J, Grace J, Fernandez H. Testosterone deficiency and apathy in Parkinson’s disease: A pilot study. J Neurol Neurosurg Psychiatry2004;75:1323-6.
100. Brown RG, Jahanshahi M, Quinn N, Marsden CD. Sexual function in patients with Parkinson’s disease and their partners. J Neurol Neurosurg Psychiatry1990;53:480-6.
101. Bronner G, Royter V, Korczyn AD, Giladi N. Sexual dysfunction in Parkinson’s disease. J Sex Marital Ther2004;30:95-105.
102. Feldman H, Goldstein I, Hatzichristou D, Krane R, McKinlay J. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
103. Lipe H, Longstreth WT, Bird TD, Linde M. Sexual function in married men with Parkinson’s disease compared to married men with arthritis. Neurology1990;40:1347-9.
104. Chandler BJ, Brown S. Sex and relationship dysfunction in neurological disability. J Neurol Neurosurg Psychiatry 1998;65:877-80.
105. Papatsoris AG, Deliveliotis C, Singer C, Papapetropoulos S. Erectile dysfunction in Parkinson’s disease. Urology 2006;67:447-51.
106. Jacobs H, Vieregge A, Vieregge P. Sexuality in young patients with Parkinson’s disease: A population based comparison with healthy controls. J Neurol Neurosurg Psychiatry 2000;69:550-2.
107. Welsh M, Hung L, Waters CH. Sexuality in women with Parkinson’s disease. Mov Disord 1997;12:923-7.
108. Wermuth L, Stenager E. Sexual problems in young patients with Parkinson’s disease. Acta Neurol Scand1995;91:453-5.
109. Heaton J. Central neuropharmacological agents and mechanisms in erectile dysfunction: the role of dopamine. Neuroscience and Behavioral Reviews2000;24:561-9.
110. Eardley I, Wright P, MacDonagh R, Hole J, Edwards A. An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. BJU Int 2004;93:1271-5.
111. O’Sullivan J, Hughes A. Apomorphine-induced penile erections in Parkinson’s disease. Mov Disord1998;13:536-9.
112. Safarinejad MR. Salvage of sildenafil failures with cabergoline: A randomized, double-blind, placebocontrolled study. Int J Impot Res 2006; 18:550-8.
113. Pohanka M, Kanovsky P, Bares M, Pulkrabek J, Rektor I. The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson’s disease induced by pergolide: Evidence from the results of an open, prospective, one-year trial. Parkinsonism Relat Disord 2005;11:509-12.
114. Zesiewicz TA, Helal M, Hauser RA. Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson’s disease. Mov Disord2000;15:305-8.
115. Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson’s disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001;71:371-4.
116. Castelli L, Perozzo P, Genesia ML, et al. Sexual well being in parkinsonian patients after deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 2004;75:1260-4.
117. Ballivet J, Marin A, Gisselmann A. Aspects of hypersexuality observed in parkinsonian patients treated by L-dopa. Ann Med Psychol (Paris)1973;2:515-22.
118. Gisselmann A. Hypersexuality and L dopa. Nouv Presse Med 1973;2:1616.
119. Brown E, Brown GM, Kofman O, Quarrington B. Sexual function and affect in parkinsonian men treated with L-dopa. Am J Psychiatry 1978;135:1552.
120. Klos KJ, Bower JH, Josephs KA, Matsumoto JY, Ahlskog JE. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson’s disease and multiple system atrophy. Parkinsonism Relat Disord 2005;11:381-6.
121. Kanovsky P, Bares M, Pohanka M, Rektor I. Penile erections and hypersexuality induced by pergolide treatment in advanced, fluctuating Parkinson’s disease. J Neurol 2002;249:112-4.
122. Shapiro MA, Chang YL, Munson SK, Okun MS, Fernandez HH. Hypersexuality and paraphilia induced by selegiline in Parkinson’s disease: report of 2 cases. Parkinsonism Relat Disord 2006;12:392-5.
123. Uitti RJ, Tanner CM, Rajput AH, et al. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol1989;12:375-83.
124. Voon V, Hassan K, Zurowski M, et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 2006;67:1254-7.
125. Fenu S, Wardas J, Morelli M. Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson’s disease. Behav Pharmacol2009;20:363-79.
126. O’Sullivan SS, Evans AH, Lees AJ. Dopamine dysregulation syndrome: An overview of its epidemiology, mechanisms and management. CNS Drugs 2009;23:157-70.
127. Bach JP, Oertel WH, Dodel R, Jessen F. Treatment of hypersexuality in Parkinson’s disease with carbamazepine - a case report. Mov Disord2009;24:1241-2.
128. Romito LM, Raja M, Daniele A, et al. Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson’s disease. Mov Disord 2002;17:1371-4.
129. Roane DM, Yu M, Feinberg TE, Rogers JD. Hypersexuality after pallidal surgery in Parkinson disease. Neuropsychiatry Neuropsychol Behav Neurol2002;15:247-51.